Full-Life wants more, acquires New Jersey biotech in efforts to dominate radiopharmaceutical R&D

Founded in 2020, Focus-X is developing several preclinical targeted radiopharmaceuticals based on peptide engineering tech that takes aim at treating cancer. Now, Full-Life—a radiotherapeutics company with operations in China and Europe—will work to advance the biotech’s compounds into clinical development and add on Focus-X’s tech as its second peptide-focused discovery platform.

Under the terms of the acquisition, which is set to close in the first quarter of 2023, Focus-X shareholders will receive an upfront payment and be eligible to receive regulatory and sales-based milestones totaling a combined $245 million,...